Gregory A Cox

Title: Gregory A. Cox: Innovator in Clinical Disorder Identification

Introduction

Gregory A. Cox is a notable inventor based in Bar Harbor, ME (US). He has made significant contributions to the field of clinical research, particularly in identifying genetic mutations associated with neurological disorders. His work has implications for understanding and diagnosing conditions such as ataxia and epilepsy.

Latest Patents

Cox holds a patent for an "In vitro method for identifying a clinical disorder associated with Nhe1." This patent discloses the identification of a mutation responsible for ataxia and epilepsy in a murine model system. Specifically, a mutation within the Nhe1 gene, also known as the Slc9a1 gene, has been identified. This mutation results in both ataxia and epilepsy, characterized by an A to T transition at nucleotide 1639, which creates a premature stop codon. The identification of this mutation enables methods for detecting clinical disorders associated with defects in cation exchangers, such as Nhe1.

Career Highlights

Throughout his career, Gregory A. Cox has worked with prestigious institutions, including The Jackson Laboratory and Baylor College of Medicine. His research has focused on the genetic underpinnings of neurological disorders, contributing to advancements in clinical diagnostics.

Collaborations

Cox has collaborated with esteemed colleagues, including Jeffrey L. Noebels and Wayne N. Frankel. These collaborations have furthered the understanding of genetic mutations and their clinical implications.

Conclusion

Gregory A. Cox's innovative work in identifying genetic mutations associated with clinical disorders highlights his significant contributions to medical research. His patent and collaborations reflect a commitment to advancing the understanding of neurological conditions.